Lucid Diagnostics Inc. (LUCD)

Market Cap	196.49M +51.1%
Revenue (ttm)	5.13M +23.0%
Net Income	-58.18M
EPS	-0.49
Shares Out	190.77M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	772,353
Open	1.050
Previous Close	1.050
Day's Range	1.025 - 1.070
52-Week Range	0.900 - 1.629
Beta	1.10
Analysts	Strong Buy
Price Target	3.90 (+278.64%)
Earnings Date	May 14, 2026

About LUCD

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company’s flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in ...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 14, 2021
• Employees: 82
• Stock Exchange: NASDAQ
• Ticker Symbol: LUCD
• Website: https://www.luciddx.com

Financial Performance

In 2025, Lucid Diagnostics's revenue was $4.71 million, an increase of 8.28% compared to the previous year's $4.35 million. Losses were -$70.57 million, 33.1% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for LUCD stock is "Strong Buy." The 12-month stock price target is $3.9, which is an increase of 278.64% from the latest price.

Price Target

$3.9

(278.64% upside)

Analyst Consensus: Strong Buy